News Articles Tagged: GLS1 Inhibitor

CB-839: A Key Pharmaceutical Intermediate for Advanced Cancer Research

Learn why CB-839 is a crucial pharmaceutical intermediate for advanced cancer research, focusing on its GLS1 inhibitory activity and therapeutic implications.

Exploring the Therapeutic Potential of GLS1 Inhibitors: The Case of CB-839

Discover the therapeutic potential of GLS1 inhibitors like CB-839 in targeting cancer's metabolic vulnerabilities, with insights for drug developers.

The Role of Glutamine Metabolism in Cancer: Insights from CB-839

Delve into the critical role of glutamine metabolism in cancer and how CB-839, a GLS1 inhibitor, provides valuable insights for therapeutic development.

Understanding Glutaminase Inhibition: The Role of CB-839 in Cancer Metabolism

Explore how CB-839, a potent GLS1 inhibitor, is revolutionizing cancer metabolism research by targeting glutamine addiction in cancer cells.